Matinas BioPharma Announces CMO Departure, Director Changes
Ticker: MTNB · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-departure, board-changes, officer-compensation
TL;DR
Matinas BioPharma's CMO is out, new directors in, and comp plans are changing.
AI Summary
Matinas BioPharma Holdings, Inc. announced on February 5, 2025, the departure of Dr. Terry H. Liang from his role as Chief Medical Officer. The company also reported on the election of new directors and changes in officer compensation arrangements.
Why It Matters
Changes in key executive positions and board composition can signal shifts in company strategy or operational focus.
Risk Assessment
Risk Level: medium — Executive departures and board changes can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- Dr. Terry H. Liang (person) — Departing Chief Medical Officer
- February 5, 2025 (date) — Date of earliest event reported
FAQ
Who has departed from Matinas BioPharma?
Dr. Terry H. Liang has departed from his role as Chief Medical Officer.
What is the effective date of the reported events?
The earliest event reported is dated February 5, 2025.
What other corporate actions are mentioned in the filing?
The filing also covers the election of directors and changes to compensatory arrangements for certain officers.
In which state is Matinas BioPharma incorporated?
Matinas BioPharma Holdings, Inc. is incorporated in Delaware.
What is the principal executive office address for Matinas BioPharma?
The principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2025-02-11 17:10:22
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-25-005948.txt ( ) — 204KB
- mtnb-20250205.xsd (EX-101.SCH) — 3KB
- mtnb-20250205_lab.xml (EX-101.LAB) — 33KB
- mtnb-20250205_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: February 11, 2025 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer